• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

    5.175 -0.125 (-2.36%)
    Streaming Delayed Price Updated: 2:28 PM EDT, Jun 10, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,603,152
    Open 5.210
    Bid (Size) 5.170 (2,500)
    Ask (Size) 5.180 (1,800)
    Prev. Close 5.300
    Today's Range 5.100 - 5.470
    52wk Range 2.450 - 6.790
    Shares Outstanding 287,686,199
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    AbCellera Appoints Dr. Victor Sandor to its Board of Directors
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    AbCellera Biologics Bets on Hot Flash Antibody as Pipeline Pivot Gains Steam ↗
    AbCellera Biologics (NASDAQ:ABCL) is emphasizing its transition from a partner-based antibody discovery business to a proprietary drug development company, Chief Financial Officer Andrew Booth said... 
    Via MarketBeat

    Performance

    YTD
    +50.9%
    +50.9%
    1 Month
    -1.4%
    -1.4%
    3 Month
    +45.0%
    +45.0%
    6 Month
    +40.6%
    +40.6%
    1 Year
    +106.2%
    +106.2%

    More News

    Read More
    News headline image
    AbCellera Biologics Q1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    AbCellera (ABCL) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    Topics Intellectual Property
    AbCellera Biologics Inc (NASDAQ:ABCL) Reports Narrower-Than-Expected Loss on Patent Settlement Windfall ↗
    Via Chartmill
    Topics Intellectual Property
    News headline image
    Earnings Scheduled For November 6, 2025 ↗
    Via Benzinga
    Stay updated with the stocks that are on the move in today's after-hours session. ↗
    Via Chartmill
    News headline image
    AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    AbCellera to Present at Upcoming Investor Conferences in May and June 2026
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    CRA: Here’s the TFSA Contribution Room for 2026 and Why Now Is the Best Time to Use It ↗
    Via The Motley Fool
    These stocks are moving in today's after hours session ↗
    Via Chartmill
    News headline image
    AbCellera Reports Full Year 2025 Business Results
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot
    Via MarketMinute
    Topics Artificial Intelligence Economy Initial Public Offering
    News headline image
    AbCellera to Present at Upcoming Investor Conferences in March and April 2026
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    AbCellera and Bruker Reach Global Settlement of Patent Litigation
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    AbCellera Appoints Dr. Stephen Quake to its Board of Directors
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    AI Stocks Extend Selloff, Nasdaq 100 Eyes Worst Week Since April: What's Moving Markets Friday? ↗
    Via Benzinga
    Topics Artificial Intelligence
    News headline image
    AbCellera Biologics Inc (NASDAQ:ABCL) Reports Mixed Q3 2025 Results with Revenue Beat and Wider Loss ↗
    Via Chartmill
    News headline image
    AbCellera Reports Q3 2025 Business Results
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    AI Stocks Slide Again, Bitcoin Dips Near $100,000: What's Moving Markets Thursday? ↗
    Via Benzinga
    Topics Artificial Intelligence

    Frequently Asked Questions

    Is AbCellera Biologics Inc. - Common Shares publicly traded?
    Yes, AbCellera Biologics Inc. - Common Shares is publicly traded.
    What exchange does AbCellera Biologics Inc. - Common Shares trade on?
    AbCellera Biologics Inc. - Common Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for AbCellera Biologics Inc. - Common Shares?
    The ticker symbol for AbCellera Biologics Inc. - Common Shares is ABCL on the Nasdaq Stock Market
    What is the current price of AbCellera Biologics Inc. - Common Shares?
    The current price of AbCellera Biologics Inc. - Common Shares is 5.175
    When was AbCellera Biologics Inc. - Common Shares last traded?
    The last trade of AbCellera Biologics Inc. - Common Shares was at 06/10/26 02:28 PM ET
    What is the market capitalization of AbCellera Biologics Inc. - Common Shares?
    The market capitalization of AbCellera Biologics Inc. - Common Shares is 1.49B
    How many shares of AbCellera Biologics Inc. - Common Shares are outstanding?
    AbCellera Biologics Inc. - Common Shares has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.